Monument Therapeutics used digital biomarkers to develop innovative new drugs for neuropsychiatric disorders including schizophrenia
Monument Therapeutics's investors include SyndicateRoom, Innovate UK, ACF Investors, GM&C Life Sciences Fund, One Mind Accelerator.
Monument Therapeutics is headquartered in Cambridge, United Kingdom.
Monument Therapeutics used digital biomarkers to develop innovative new drugs for neuropsychiatric disorders including schizophrenia
Monument Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Monument Therapeutics — Funding & Investors." VCBacked, February 9, 2026, https://www.vcbacked.co/company/monument-therapeutics. Accessed October 4, 2026.
VCBacked. (2026). Monument Therapeutics — Funding & Investors. Retrieved October 4, 2026, from https://www.vcbacked.co/company/monument-therapeutics
{{cite web |title=Monument Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/monument-therapeutics |website=VCBacked |access-date=October 4, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated